TrialBMC cancer2024

Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.

Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.